- Home
- FULC vs PRAA Comparison
FULC vs PRAA Comparison
Compare FULC & PRAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FULC | PRAA |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | United States | United States |
| Employees | N/A | 170 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 718.4M | 639.1M |
| IPO Year | 2019 | 2002 |
Fundamental Metrics
Financial Performance| Metric | FULC | PRAA |
|---|---|---|
| Price | $7.93 | $18.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | $16.38 | ★ $24.50 |
| AVG Volume (30 Days) | ★ 1.0M | 672.4K |
| Earning Date | 05-19-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,201,837,000.00 |
| Revenue This Year | N/A | $2.01 |
| Revenue Next Year | N/A | $2.53 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 7.83 |
| 52 Week Low | $2.32 | $10.25 |
| 52 Week High | $15.74 | $22.01 |
Technical Indicators
Market Signals| Indicator | FULC | PRAA |
|---|---|---|
| Relative Strength Index (RSI) | 34.80 | 72.31 |
| Support Level | $6.33 | $13.16 |
| Resistance Level | $8.50 | $19.83 |
| Average True Range (ATR) | 0.80 | 1.03 |
| MACD | -0.17 | 0.90 |
| Stochastic Oscillator | 9.31 | 91.30 |
Price Performance
Historical ComparisonAbout FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About PRAA PRA Group Inc.
PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.